New Ray Medicine International Holding Limited (HKG:6108)
Hong Kong · Delayed Price · Currency is HKD 0.2260
+0.0160 (7.62%)
Sep 29, 2026, 4:08 PM HKT
HKG:6108 Financials Overview
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 199.09 | 130.37 | 93.95 | 50.15 | 89.77 | 335.38 |
Revenue Growth | 52.71% | 38.78% | 87.31% | -44.13% | -73.23% | 151.76% |
Gross Profit Gross Profit Growth | 22.36 | 16.15 | -1.62 | 11.34 | -29.18 | 28.49 |
Operating Income Operating Income Growth | -13 | -16.3 | -37.94 | -21.42 | -73.42 | -7.08 |
Net Income Net Income Growth | -16.18 | -20.07 | -31.01 | -22.17 | -77.95 | -2.82 |
Earnings Per Share EPS Growth | -0.09 | -0.12 | -0.19 | -0.13 | -0.47 | -0.02 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Distribution and Trading of Pharmaceutical Products Distribution and Trading of Pharmaceutical Products Growth | 197.49 | 127.93 | 88.71 | 42.85 | 83.75 | 329.62 |
Provision of Marketing and Promotion Services of Drugs Provision of Marketing and Promotion Services of Drugs Growth | 1.61 | 2.44 | 5.24 | 7.3 | 6.02 | 5.76 |
Total Total Growth | 199.09 | 130.37 | 93.95 | 50.15 | 89.77 | 335.38 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 73.58 | 37.42 | 64.26 | 103.95 | 154.41 | 150.15 |
Total Debt Total Debt Growth | 2.12 | 2.47 | 3.55 | 0.29 | 1.28 | 12.84 |
Net Cash (Debt) Net Cash Growth | 71.46 | 34.96 | 60.71 | 103.67 | 153.14 | 137.31 |
Net Cash Growth | 104.43% | -42.42% | -41.44% | -32.30% | 11.52% | 116.73% |
Net Cash Per Share Net Cash Per Share Growth | 0.39 | 0.21 | 0.36 | 0.62 | 0.92 | 0.82 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 11.24 | -54.14 | -4.77 | -45.41 | -0.32 | -58.39 |
Capital Expenditures CapEx Growth | -0.31 | -0.31 | -0.62 | -0.04 | -8.7 | -0.06 |
Free Cash Flow Free Cash Flow Growth | 10.93 | -54.45 | -5.39 | -45.45 | -9.02 | -58.45 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 11.23% | 12.39% | -1.73% | 22.61% | -32.51% | 8.49% |
Operating Margin | -6.53% | -12.50% | -40.38% | -42.71% | -81.78% | -2.11% |
Pretax Margin | -8.06% | -15.30% | -34.13% | -44.55% | -89.43% | -1.08% |
Profit Margin | -8.13% | -15.39% | -33.01% | -44.20% | -86.83% | -0.84% |
FCF Margin | 5.49% | -41.77% | -5.73% | -90.62% | -10.04% | -17.43% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 18.72 | 18.72 | 18.72 | 18.72 | 18.72 |
PS Ratio | 0.23 | 0.42 | 0.80 | 1.67 | 1.77 | 2.12 |